Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.53 |
| ▸ | CD74 | P04233 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | DDT | P30046 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.43 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.43 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9134467 | 0.75 | KMO (0.51) | KMOCD74MIFHDAC1HDAC6 | |
| SCHEMBL71238 | 0.75 | KMO (0.86) | KMOCD74MIFRXRARXRB | |
| SCHEMBL30725957 | 0.75 | KMO (0.86) | KMOCD74MIFRXRARXRB | |
| SCHEMBL29904709 | 0.75 | KMO (0.86) | KMOCD74MIFRXRARXRB | |
| SCHEMBL2988942 | 0.74 | DHODH (0.51) | RXRARXRBMAPK1MAP2K4MAPKAPK3 | |
| Hydrochloric Acid SCHEMBL21173951 | 0.73 | KMO (0.83) | KMOCD74MIFRXRARXRB | |
| Hydrochloric Acid SCHEMBL4350309 | 0.73 | KMO (0.83) | KMOCD74MIFRXRARXRB | |
| Fluoride SCHEMBL21332075 | 0.73 | KMO (0.83) | KMOCD74MIFRXRARXRB | |
| Water SCHEMBL10348973 | 0.73 | KMO (0.83) | KMOCD74MIFRXRARXRB | |
| SCHEMBL29276453 | 0.73 | KMO (0.83) | KMOCD74MIFRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20150164912-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2015-06-18 | — | — | US | disclosed |
| US-8933109-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA LIMITED (GB) | 2015-01-13 | — | — | US | disclosed |
| US-20140038944-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| US-8552202-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2013-10-08 | — | — | US | disclosed |
| US-20130150345-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2013-06-13 | — | — | US | disclosed |
| US-8389737-B2 | Furo[3, 2-B] pyrrol-3-ones as cathespin S inhibitors | AMURA THERAPEUTICS LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| EP-2297162-B1 | COMPOUNDS | AMURA THERAPEUTICS LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| EP-2283022-B1 | FURO [3, 2-B]PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2012-07-18 | — | — | EP | disclosed |
| US-8008290-B2 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2011-08-30 | — | — | US | disclosed |
| EP-2297162-A1 | COMPOUNDS | Amura Therapeutics Limited (GB) | 2011-03-23 | — | — | EP | disclosed |
| EP-2283022-A1 | FURO Ý3, 2-B¨PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | Amura Therapeutics Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| US-20110009385-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| WO-2009112839-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112826-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150345-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KMO 546/4885CD74 1040/4885MIF 984/4885 |
| US-20110009385-A1 | COMPOUNDS | CTSK, CTSS, MMP9 | KMO 2550/4885CD74 3187/4885MIF 841/4885 |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KMO 495/4885CD74 830/4885MIF 1358/4885 |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KMO 546/4885CD74 1040/4885MIF 984/4885 |
| US-20150164912-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KMO 546/4885CD74 1040/4885MIF 984/4885 |
| US-20140038944-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KMO 546/4885CD74 1040/4885MIF 984/4885 |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KMO 495/4885CD74 830/4885MIF 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.